San Mateo-based digital health company, RapidAI, has raised $75 million in Series C funding, led by Vista Credit Partners, a subsidiary of Vista Equity Partners. RapidAI develops artificial intelligence and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases. The funding will be used to drive platform innovation to support more disease states and expand go-to-market functions in new regions and product verticals. RapidAI’s AI and workflow technology sets the standard for stroke care, offering FDA-cleared solutions for intracranial hemorrhage, large vessel occlusion, cerebral aneurysm management, and suspected central pulmonary embolism.
What You Should Know:
– RapidAI, a San Mateo, CA-based digital health company developing artificial intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, today announced $75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the enterprise software, data and technology markets.
– The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Clinical Decision Making & Workflow
RapidAI’s pioneering AI and workflow technology sets the standard for stroke care – the second leading cause of death globally. The company has built a comprehensive portfolio of stroke solutions, including Rapid NCCT Stroke – the first and only FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from non-contrast CT imaging. Rapid NCCT Stroke provides hospitals of all sizes and imaging capabilities greater access to imaging and decision support to address a wider population of patients. RapidAI has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolism. The company is also developing additional modules for other disease states.
Source: HitConsultant